Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Shares Outstanding (Weighted Average) (2016 - 2025)

Dexcom (DXCM) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $390.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) fell 0.86% to $390.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $390.2 million, a 0.86% decrease, with the full-year FY2025 number at $390.2 million, down 0.86% from a year prior.
  • Shares Outstanding (Weighted Average) was $390.2 million for Q4 2025 at Dexcom, roughly flat from $391.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $399.2 million in Q2 2024 to a low of $96.3 million in Q1 2021.
  • A 5-year average of $375.1 million and a median of $389.6 million in 2022 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 313.01% in 2021, then decreased 1.9% in 2025.
  • Dexcom's Shares Outstanding (Weighted Average) stood at $386.9 million in 2021, then rose by 0.65% to $389.4 million in 2022, then fell by 0.87% to $386.0 million in 2023, then grew by 1.97% to $393.6 million in 2024, then decreased by 0.86% to $390.2 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Shares Outstanding (Weighted Average) are $390.2 million (Q4 2025), $391.1 million (Q3 2025), and $391.6 million (Q2 2025).